Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,041
datasets available to search
ShareScore release 0.9.0
Dataset results
1,041 results for “targeted therapy”
Targeting redox-sensitive MBD2-NuRD condensate for tumor therapy [ATAC-seq]
GEO Series GSE270303. Homo sapiens. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Final efficacy and biomarker analysis of the sorafenib arm of the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial
GEO Series GSE31428. Homo sapiens. 37 samples. Type: Expression profiling by array.
Inhibiting the mammalian target of rapamycin (mTOR) as an adjunctive therapy for cerebral malaria
GEO Series GSE64702. Mus musculus. 64 samples. Type: Expression profiling by array.
A molecular signature for MET-targeted therapy
GEO Series GSE64667. Homo sapiens; Mus musculus. 56 samples. Type: Expression profiling by array.
Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy [array]
GEO Series GSE280642. Homo sapiens. 24 samples. Type: Expression profiling by array.
Immunogenic Senescence Sensitizes Lung Cancer to LUNX-Targeting Therapy
GEO Series GSE185209. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Targeting redox-sensitive MBD2-NuRD condensate for tumor therapy [CUT&Tag]
GEO Series GSE270304. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Disruption of the Fgfr1-Fgf23-Phosphate Axis and Targeted Therapy in a Murine Model of Osteoglophonic Dysplasia
GEO Series GSE306640. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing.
Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models [CUT&RUN]
GEO Series GSE240495. Homo sapiens. 6 samples. Type: Other.
Growth factor independence 1 (Gfi1) as a new target for leukemia therapy
GEO Series GSE32910. Mus musculus. 20 samples. Type: Expression profiling by array.
Hypoxia PET Imaging Identifies Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy to Rescue Checkpoint Blockade Refractory Tumors
GEO Series GSE184863. Mus musculus. 16 samples. Type: Expression profiling by array.
Single-cell transcriptomic profiling reveals the heterogeneity of miR-18a-mediated resistance to targeted therapy and immunotherapy in melanoma
GEO Series GSE318353. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy
GEO Series GSE86445. Homo sapiens. 6 samples. Type: Expression profiling by array.
Combinational targeting CCL7 and Flt3L to promote the expansion and infiltration of cDC1 in tumors enhances T cell activation and anti-PD-1 therapy [Dendritic Cell]
GEO Series GSE225126. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
mRNA/sRNA Co-Sequencing Reveals Multiple New Targeted Therapy Candidates in Rhabdomyosarcoma [miRNA-seq]
GEO Series GSE280045. Homo sapiens. 14 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Development of a benzarone derivative as targeted therapy for SHH-medulloblastoma
GEO Series GSE229194. Mus musculus. 14 samples. Type: Expression profiling by high throughput sequencing.
Combinational targeting CCL7 and Flt3L to promote the expansion and infiltration of cDC1 in tumors enhances T cell activation and anti-PD-1 therapy [CD8 T]
GEO Series GSE225163. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Epigenetic targeted therapy of leukemia through a hyper-activated BAP1-ASXL1-mutant axis
GEO Series GSE166305. Homo sapiens. 78 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Dataset related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"
<p>This record contains raw data related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Radiotherapy is essential in the management of head-neck cancer. During the course of radiotherapy, patients may develop significant anatomical changes. Re-planning with adaptive radiotherapy may ensure adequate dose coverage and sparing of organs at risk. We investigated the consequences of adaptive radiotherapy on head-neck cancer patients treated with volumetric-modulated arc radiation therapy compared to simulated non-adaptive plans: Materials and methods: We included in this retrospective dosimetric analysis 56 patients treated with adaptive radiotherapy. The primary aim of the study was to analyze the dosimetric differences with and without an adaptive approach for targets and organs at risk, particularly the spinal cord, parotid glands, oral cavity and larynx. The original plan (OPLAN) was compared to the adaptive plan (APLAN) and to a simulated non-adaptive dosimetric plan (DPLAN).</p><p><strong>Results: </strong>The non-adaptive DPLAN, when compared to OPLAN, showed an increased dose to all organs at risk. Spinal cord D2 increased from 27.91 (21.06-31.76) Gy to 31.39 (27.66-38.79) Gy (<i>p</i> = 0.00). V15, V30 and V45 of the DPLAN vs. the OPLAN increased by 20.6% (<i>p</i> = 0.00), 14.78% (<i>p</i> = 0.00) and 15.55% (<i>p</i> = 0.00) for right parotid; and 16.25% (<i>p</i> = 0.00), 18.7% (<i>p</i> = 0.00) and 20.19% (<i>p</i> = 0.00) for left parotid. A difference of 36.95% was observed in the oral cavity V40 (<i>p</i> = 0.00). Dose coverage was significantly reduced for both CTV (97.90% vs. 99.96%; <i>p</i> = 0.00) and PTV (94.70% vs. 98.72%; <i>p</i> = 0.00). The APLAN compared to the OPLAN had similar values for all organs at risk.</p><p><strong>Conclusions: </strong>The adaptive strategy with re-planning is able to avoid an increase in dose to organs at risk and better target coverage in head-neck cancer patients, with potential benefits in terms of side effects and disease control.</p>
New Strategy for the Development of Targeted Drug Delivery Systems in Cancer Therapy
<p>Rare dataset of the experiments performed during the investigation of our newly developed SREKA pentapeptide, and its use for liposome preparation.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.